Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study-Reference-Cited by-同舟云学术

Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study

Published:2017-05-26 Issue:3 Volume:102 Page:547-553
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Agergaard K¹,Mau-Sørensen M²,Stage TB¹³,Jørgensen TL⁴⁵,Hassel RE⁶,Steffensen KD⁷,Pedersen JW⁸,Milo MLH⁹,Poulsen SH²,Pottegård A¹,Hallas J¹,Brøsen K¹¹⁰,Bergmann TK¹¹¹²

Affiliation:

1. Clinical Pharmacology and Pharmacy; Department of Public Health, University of Southern Denmark; Odense Denmark

2. Department of Oncology; Rigshospitalet, Copenhagen University Hospital; Copenhagen Denmark

3. Department of Bioengineering and Therapeutics Sciences; University of California San Francisco; San Francisco California USA

4. Department of Oncology; Odense University Hospital; Odense Denmark

5. AgeCare, Academy of Geriatric Cancer Research; Odense University Hospital; Odense Denmark

6. Department of Oncology; Aarhus University Hospital; Aarhus Denmark

7. Department of Oncology; Lillebaelt Hospital; Vejle Denmark

8. Department of Oncology; Herlev Hospital, Copenhagen University Hospital; Herlev Denmark

9. Department of Oncology; Aalborg University Hospital; Aalborg Denmark

10. OPEN; Odense Patient Data Explorative Network, Odense University Hospital; Odense Denmark

11. Department of Clinical Biochemistry and Pharmacology; Odense University Hospital; Odense Denmark

12. Hospital Pharmacy; Hospital of South West Denmark; Esbjerg Denmark

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference19 articles.

1. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer;Gianni;J. Clin. Oncol.,2009

2. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group);McGuire;Semin. Oncol.,1996

3. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma;Vasey;J. Natl. Cancer Inst.,2004

4. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer;Weissman;J. Thorac. Oncol.,2011

5. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer;Belani;Ann. Oncol.,2005

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling mechanisms of chemotherapy-induced peripheral neuropathy and chemotherapy transport using induced pluripotent stem cell-derived sensory neurons;Neuropharmacology;2024-11

2. COMPARATIVE EVALUATION OF ARTIFICIAL INTELLIGENCE AND DRUG INTERACTION TOOLS: A PERSPECTIVE WITH THE EXAMPLE OF CLOPIDOGREL;Ankara Universitesi Eczacilik Fakultesi Dergisi;2024-08-05

3. Innovative strategies for effective paclitaxel delivery: Recent developments and prospects;Journal of Oncology Pharmacy Practice;2024-01-10

4. MecDDI: Clarified Drug–Drug Interaction Mechanism Facilitating Rational Drug Use and Potential Drug–Drug Interaction Prediction;Journal of Chemical Information and Modeling;2023-02-20

5. Paclitaxel- and vincristine-induced neurotoxicity and drug transport in sensory neurons;2023-02-07